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El trastorno por uso de krokodil es una de las patologías adictivas con 
mayores repercusiones orgánicas, principalmente a nivel cutáneo, 
produciendo una grave y degenerativa necrosis del tejido sanguíneo 
y muscular. Se trata de un trastorno con escasa prevalencia en 
España, frente al elevado número de consumidores en otros países 
como Ucrania o Rusia, si bien se está produciendo una lenta aunque 
gradual expansión del consumo en países de la Unión Europea y del 
continente americano. El sencillo proceso de obtención de la sustancia 
desde la desomorfina, unido a la elevada disponibilidad y bajo coste, 
configura el proceso de autoabastecimiento de los consumidores. En 
este artículo revisamos un cuadro clínico, presentando el caso de un 
paciente que consume krokodil por vía oral.
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The krokodil use disorder is an addictive pathology with quite 
severe organic effects, especially at the skin level, that causes severe 
and degenerative necrosis of blood and muscle tissue. Though 
this disorder has a low prevalence in Spain, compared to the large 
number of consumers in other countries such as Ukraine or Russia, 
its consumption is slowly but gradually expanding in countries of 
the European Union and America. The simplicity of the process of 
obtaining the substance from desomorphine, together with its high 
availability and low cost, contribute toward consumers’ self-sufficiency. 
This article presents the case of a user of krokodil and reviews the 
clinical symptoms of oral ingestion.
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Desomorphine or krokodil is one of the most-fre-quently consumed substances in some coun-tries of northern Europe and the former Soviet Union, and is quickly expanding through the 
United States and South America. At the same time, given its 
high addictiveness, low cost and ready availability, as well as 
the incidence of serious organic pathologies associated with 
its use, its social and health-related repercussions for the 
user demand attention (Heimer, 2013). Despite the start of 
its consumption in Russia, Ukraine and Georgia at the end of 
the last century, clinical interest in the use of krokodil is cu-
rrently under focus due to its potential organic deterioration 
and addictiveness for the user. Determinant factors also exist 
behind the great social alarm and media coverage given to 
the process of krokodil use as a whole. One of these aspects 
is the easy access to the substance, starting with the rudimen-
tary, home-based synthesis of krokodil; another determinant 
is the dissemination of the users’ serious clinical symptoms 
exhibited by media sources and the Internet (Gahr et al., 
2012). Over the last five years, a growing number of reports 
on the prevalence of substance use claim a notable reduction 
of inhaled opium and parenteral consumption of heroin in 
Russia, Ukraine, Kazakhstan and Georgia, while at the same 
time reporting a notable increase of the use of drugs con-
taining codeine (Solpadeine, Codterpin or Codelac) used for 
producing desomorphine (Savchuk, Barsegyan, Barsegyan & 
Kolesov, 2008). The ongoing economic crisis of these coun-
tries, together with the relative availability of legal precursors 
at pharmacies, promotes, to date, a culture of homemade 
substances, like alcohol, krokodil or -as an example of the 
abovementioned- the use of Pervitin (methamphetamine) in 
Prague since the early 1980s (Zabransky et al., 2012).
This self-supply model differs from that of other coun-
tries, where drug trafficking dominates drug production 
and distribution. Apparently economic factors are the de-
terminants of krokodil use (Grund, 2002), as there is alre-
ady proof of the home-based manufacturing of desomorphi-
ne in areas with high unemployment rates and economic 
problems, as is the case in some states of the United States, 
Mexico and Holland (Kwint, Kruizinga, Kaal & Bootsma, 
2013). 
The molecule dihydrodesoxymorphine: C17H21NO2, 
desomorphine, or the brand name Permonid, is similar to 
the opioid synthesized in 1932 in the United States by the 
chemist Lyndon Frederic Pequeño. Desomorphine is a de-
rivative of morphine with the elimination of the 6-hydroxyl 
group and the reduction of the 7,8 double bond. Traditio-
nal synthesis of desomorphine is based on α-chlorocodide, 
in turn obtained by provoking a reaction of thionyl chloride 
with codeine. Through catalytic reduction, the α-chloroco-
dide produces dihydrodesoxycodeine, which through de-
methylation leads to the formation of desomorphine (Eddy, 
Halbach & Braenden, 1957) (Figure 1). Given its structural 
similarity to morphine, it is suggested that desomorphine 
is a potent mu opioid agonist with higher toxicity and anal-
gesic power of between 5-10 greater than morphine. The 
effect of desomorphine is produced approximately two mi-
nutes after consumption, and lasts, on the average, between 
60 and 90 minutes (Eddy & Howes, 1935).
Figure 1.
The leading and diverse medical purposes for which 
desomorphine or Permonid® was sold as hydrobromic acid 
salt included analgesic, antitussive and even sedative uses. 
However, its side effects (hypotension, urinary retention, 
vomiting and drowsiness) together with a fast development 
of addiction in humans, resulted in its withdrawal from the 
market (Matiuk, 2014).
The neologism krokodil arises from its pronunciation 
similar to chlorocodide, as well as for the lesions users su-
ffer at the epithelial level, which with a greenish hue and 
scaly appearance remind us of the skin of a crocodile. Ela-
borating the substance is simple and inexpensive. In most 
cases, patients manufacture krokodil in their own home by 
combining hydrochloric acid, iodine and red phosphorus 
with codeine, though different preparations, like organic 
solvents or tropicamide, cheapen the process. This proce-
dure is similar to the synthesis of methamphetamine from 
pseudoephedrine (Abdala, Grund, Tolstov, Kozlov & Hei-
mer, 2006). 
The main ingestion routes of krokodil are oral and pa-
renteral, the latter entailing serious consequences for the 
organism, including HCV and HIV infections and even pro-
voking endocarditis. Injuries associated with the injection 
of krokodil are considered serious and are unprecedented 
within physical consequences of drug use. The main focus 
of clinical concern, and the greatest complication resulting 
	  
Figure 1. Synthesis of desomorphine using codeine
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of the use of krokodil, are its effects on blood tissue: abs-
cesses, phlebitis, thrombophlebitis, hemorrhages and ulcers 
that appear close to the injection site, as well as damage to 
muscles, soft tissues and bones, with fast necrosis and gan-
grene. In most cases, interventions for these conditions re-
quire extremely complicated surgeries with serious afterma-
ths, such as surgically removing the main veins from arms or 
legs, sometimes requiring amputation or skin grafts (Demi-
dova & Mokhachev, 2011). The toxic effects of krokodil are 
not only limited to muscular vascular lesions; the substan-
ce’s toxic components, like iodine, damage the thyroid and 
muscles, and phosphorus seriously deteriorates cartilage 
(Harris, 2013). In turn, these toxic compounds damage the 
neurological and endocrine systems, as well as the organs 
that intervene in the metabolism of chemical products and 
heavy metals used in the substance’s synthesis. The initial 
symptoms appear just a few days after the first intravenous 
krokodil injection and include organic symptoms, the most 
common of which are: pneumonia, meningitis, periodon-
titis and osteomyelitis. This process and the organic symp-
toms together result in users’ gradual physical deterioration 
with very high mortality rates, though not all users experi-
ment the extreme harm associated with krokodil (Grund, 
Latypov & Harris, 2013).  
The psychological consequences of use are usually not as 
defined. Together with the evident and progressive process 
of substance dependency there also coexists notable neuro-
logical damage, speech impediments, loss of motor skills, al-
tered memory, mood disorders and even psychotic episodes 
(Matiuk, 2014).
Clinical case presentation
Our case is a 34-year-old male user of the services provi-
ded by CIBE in Castellón de la Plana, with prenatal and per-
inatal developmental stages unmarked by any events worth 
highlighting. As to medical evaluations, no data of interest 
are detected, with a medical examination and blood test 
completed in September 2014, with no relevant alterations 
in blood range parameters. He has a secondary level educa-
tion level, is currently unemployed, and his stable partner 
inhales cocaine regularly. As an adult, he was imprisoned 
for 5 months. The most noteworthy fact of his family back-
ground is his father’s alcohol use disorder. 
His first experimental use of cannabis and alcohol began 
during adolescence, snorting cocaine at age 19, followed 
by habitually smoking cocaine and heroin as of the age of 
20, while occasionally abusing of benzodiazepines ingested 
orally. The patient underwent different detoxification treat-
ments at the Hospital Detoxification Unit and addiction 
treatment programs at the In-patient Drug Addiction Unit, 
was discharged and now alternates periods of abstinence 
and active use. Currently, the patient undergoes no type of 
treatment and has a disorder from using benzodiazepines, 
cocaine and smoking heroin.  
As to the reason for his visit, the patient mentions ha-
ving acquired and consumed krokodil orally, combined 
with a caffeinated beverage as a recreational experiment. 
He mentions the substance’s distinct bitter taste, even when 
dissolved in the mix, and mentions detecting its effects 20 
minutes after ingesting it. The patient describes the effects 
as itchiness across the entire body, increased temperature 
of the stomach that rises up toward the head, sweating, alte-
red breathing and an evident slowing down, headache and 
a noticeable sensation of relaxation and sedation of the rest 
of the body. The patient describes this like “the effect of 
heroin but much more physical, stronger” and despite his 
previous experience with opioid use, describes these symp-
toms as more greatly affecting the organs while disassocia-
ted from the intoxication or abstinence syndrome inherent 
to heroin. Interference on behavior of these is minimal, as 
the patient can continue with his normal functions. At the 
same time, he does not report any serious alterations to his 
judgment, will or consciousness, though he does mention 
symptoms of moderate anxiety and slight depersonalization.
Two hours after the ingestion, the patient experiences 
vomiting and stomach ache and progresses from feeling 
slightly feverish to having fever, congruent with a possible 
indigestion or gastroenteritis. The patient does not associate 
this with the use of krokodil and evolves favorably, under the 
care of the primary care system during three days.
Discussion
This case entails the oral ingestion of krokodil, wherefore 
we detect the first case of krokodil use in Spain. Seemingly, 
the expansion to Europe of krokodil use is associated with 
the economic crisis, as this is possibly the cause behind the 
appearance of the first use in Spain, where an increased use 
of amphetamine derivatives, such as α-Hydroxybutyric acid 
(GHB) or ketamine (Nogué, Amigó & Galicia, 2014), has 
also been detected.
In this case, the oral ingestion of the substance is worth 
highlighting, as opposed to the higher prevalence of the pa-
renteral route, given the scarce evidence of alternate forms 
of use (Merkinaite, Grund & Flimpond, 2010). In an initial 
phase, the physical symptoms and mental effects as percei-
ved by the patient are verified, while confirming the use of 
opioids with a urine drug test. It would be convenient to 
perform more specific toxicological analyses for purpose 
of detecting new, emerging drugs or substances that fall 
beyond the scope of classical analysis types. The detected 
symptoms are inherent to the effects of opioid use, yet si-
multaneously display other, less-specific symptoms. These 
clinical symptoms detected in the patient after consumption 
could comprise a lighter version of the symptoms of intoxi-
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cation by opioids with effects on the central nervous system 
and digestive system.
Krokodil consumption presents serious physical symp-
toms associated with the ingestion route, mainly as regards 
parenteral ingestion, such abscesses, phlebitis, throm-
bophlebitis, hemorrhages and ulcers (Rhodes, 2009). 
However, the patient does not show signs of intravenous 
krokodil injection but rather, the possible consequences of 
consumption associated with oral ingestion. The patient was 
monitored since 2008 by the CIBE assistance unit, without 
having been detected any type of psychopathological alte-
ration in previous periods of intervention, assessment and 
follow-up. Nevertheless, psychopathological repercussions 
of occasional krokodil use are not significant.
The expansion and use of krokodil is a reality in Europe, 
and given this case, we can confirm the start of its use in 
Spain. For this reason, healthcare professionals, at both le-
vels of primary care and emergency rooms, as well as mental 
health and addiction-related services, must be watchful to 
detect intoxications, abstinence syndromes or physical and/
or psychopathological effects of its use.
Acknowledgements
Publication funded by Fundación Hospital Provincial de 
Castellón, reference CAF-16/017.
Conflict of interests
The authors declare the inexistence of conflicts of interest.
References
Abdala, N., Grund, J. P., Tolstov, Y., Kozlov, A. P., & Heimer, 
R. (2006). Can homemade injectable opiates contribute 
to the HIV epidemic among injection drug users in the 
countries of the former Soviet Union? Addiction, 101, 
731–737. 
Demidova, O. V., & Mokhachev, S. O. (2011). Brief report 
about 68 cases of desomorphine misuse. Narcologiya, 10, 
96–98.
Eddy, N, B., Halbach, H., & Braenden, O. J. (1957). Synthe-
tic substances with morphine-like effect. Bulletin of the 
World Health Organization, 569–863.
Eddy, N. B., & Howes, H. (1935). Studies of Morphine, 
Codeine and their Derivatives X. Desoxymorphine-C, 
Desoxycodeine-C and their Hydrogenated Derivatives. 
Journal of Pharmacology and Experimental Therapy, 55, 257–
267.
Gahr, M., Freudenmann, R.W., Hiemke, C., Gunst, I. M., 
Connemann, B. J., & Schonfeldt-Lecuona, C. (2012). 
Desomorphine goes crocodile. Journal of Addictive Disor-
ders, 31, 407-412.
Grund, J.P., Latypov, A., & Harris, M. (2013). Breaking 
worse: the emergence of krokodil and excessive injuries 
among people who inject drugs in Eurasia. International 
Journal of Drug Policy, 24, 265-274.
Grund J. P. (2002). A candle lit from both sides: The epi-
demic of HIV infection in Central and Eastern Europe. 
In K. McElrath (Eds.), HIV and AIDS: A global view. (pp. 
41-68). Westport, CT: Greenwood Press. 
Heimer, R. (2013). Patterns of new drug emergence: A com-
ment in light of ‘krokodil’. International Journal of Drug 
Policy, 24, 275-277. doi:10.1016/j.drugpo.2013.06.003.
Harris, M. (2013). The ‘do-it-yourself’ New Zealand injec-
ting scene: Implications for harm reduction. Internatio-
nal Journal of Drug Policy, 24, 281–283. 
Kwint, H. M., Kruizinga, S. P., Kaal, M. J. H., & Bootsma, H. 
P. R. (2013). Gevaarlijke designer drug ‘krokodil’ voor 
het eerst in Nederland. Pharmaceutisch Weekblad Wetens-
chappelijk Platform, 7, 128-130.
Matiuk, D. M. (2014). Krokodil: A Monstrous Drug with 
Deadly Consequences. Journal of Addictive Disorders, 1-14.
Merkinaite, S., Grund, J. P., & Flimpond, A. (2010). Young 
people and drugs: Next generation of harm reduction. 
International Journal of Drug Policy, 21, 112-114.
Nogué, S., Amigó, M., & Galicia, M. (2014). Raves, consu-
mo de drogas y asistencia en urgencias. Adicciones, 26, 
189-190.
Rhodes, T. (2009). Risk environments and drug harms: A 
social science for harm reduction approach. Internatio-
nal Journal of Drug Policy. 20, 193–201.
Savchuk, S. A., Barsegyan, S. S., Barsegyan, I. B., & Koles-
ov. G. M. (2008). Chromatographic study of expert and 
biological samples containing desomorphine. Journal of 
Analytical Chemistry. 63, 361–370.
Zabransky, T., Grund, J. P., Latypov, A., Otiashvili, D., Stui-
kyte, R., Scutelniciuc, O., … Smyrnov, P. (2012). Harm 
reduction in Central and Eastern Europe. In R. Pates, 
and D. Riley (Eds.), Harm reduction in substance use and 
high-risk behaviour: International policy and practice sum-
maries. (pp. 301-321). Oxford: Wiley-Blackwell.
